Micro<scp>RNA</scp>‐9 inhibits the gastric cancer cell proliferation by targeting <scp>TNFAIP</scp>8

Gao, Hongyu; Huo, Fu‐Chun; Wang, Haiyan; Pei, Dong‐Sheng

doi:10.1111/cpr.12331

Cited by 32 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 Then, TNFAIP8 overexpression was found in various tumor cells such as breast cancer cells, non-small cell lung cancer (NSCLC) cells, gastric cancer cells and so on. 45…”

Section: Tnfaip8 Basic Characteristics Of Tnfaip8mentioning

confidence: 99%

“…76 Recently, many studies on Chinese population suggested that TNFAIP8 expression was related to other tumors such as thyroid papillary carcinoma, epithelial ovarian cancer, gastric cancer and esophageal squamous cell carcinoma. 42,45,47,[77][78][79][80] A study showed that TNFAIP8 overexpression was not obviously related with the prognosis of gastric cancer patients, but it was an independent prognostic factor for disease-free survival (DFS) and overall survival (OS) in patients with intestinal type of gastric cancer. 49 Recent studies related to TNFAIP8 and gastric cancer had focused on miRNAs, and it was well known that abnormal regulation of miRNAs could affect proliferation, apoptosis, invasion and metastasis in the development of tumors.…”

Section: Tnfaip8 and Malignant Tumorsmentioning

confidence: 99%

“…The results confirmed that miR-9-TNFAIP8 might be a promising predictive and prognostic biomarker for gastric cancer. 45 A review on TNFAIP8 showed that overexpression of TNFAIP8 significantly improved vascular endothelial growth factor receptor 2 (VEGFR2), MMP-1, and MMP-9 levels in breast cancer cells, thereby promoting cancer cells to metastasize. It is suggested that high-risk breast cancer patients with TNFAIP8 overexpression possessed shorter OS and DFS.…”

Section: Tnfaip8 and Malignant Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

Guo¹,

Yuan²

2020

OTT

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) is the first cytokine used in tumor biotherapy, but TNFrelated drugs are limited by the lack of specific targets. Tumor necrosis factor alpha-induced proteins (TNFAIPs), derived from TNF, is a protein family and participates in proliferation, invasion and metastasis of tumor cells. In order to better understand biological functions and potential roles of TNFAIPs in malignant tumors, this paper in the form of "Gene-Protein-Tumor correlation" summarizes the biological characteristics, physiological functions and mechanisms of TNFAIPs by searching National Center of Biotechnology Information, GeneCards, UniProt and STRING databases. The relationship between TNFAIPs and malignant tumors is analyzed, and protein-protein interaction diagram in members of TNFAIPs is drawn based on TNF for the first time. We find that TNF as a key factor is related to TNFAIP1, TNFAIP3, TNFAIP5, TNFAIP6, TNFAIP8 and TNFAIP9, which can be directly involved in activating TNFAIP1, TNFAIP5, TNFAIP8 and TNFAIP9. We confirm that the mechanism of TNFAIP1, TNFAIP2 and TNFAIP3 inducing tumors may be related to NF-κB signaling pathway, but the mechanism of tumor induction by other members of TNFAIPs is not clear. In the future, translational studies are needed to explore the mechanisms of TNF-TNFAIPs-tumors.

show abstract

“…44 Then, TNFAIP8 overexpression was found in various tumor cells such as breast cancer cells, non-small cell lung cancer (NSCLC) cells, gastric cancer cells and so on. 45…”

Section: Tnfaip8 Basic Characteristics Of Tnfaip8mentioning

confidence: 99%

Section: Tnfaip8 and Malignant Tumorsmentioning

confidence: 99%

Section: Tnfaip8 and Malignant Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

Guo¹,

Yuan²

2020

OTT

View full text Add to dashboard Cite

show abstract

“…miRNAs act as key regulators in a wide variety of physiological and pathological processes, such as cell proliferation, cycle, differentiation, apoptosis, metabolism and death (15)(16)(17). An increasing number of studies reported miRNA dysregulation in various kinds of human cancers, such as gastric cancer (18), glioma (19), lung cancer (20), bladder cancer (21) and RB (22). The abnormally expressed miRNAs are involved in progression and development of various cancers and serve as oncogenic and tumour suppressors by directly targeting the oncogenes and tumour-suppressor genes, respectively (23-25).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-382 inhibits cell proliferation and invasion of retinoblastoma by targeting BDNF-mediated PI3K/AKT signalling pathway

Song

Diao

Yang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

It has previously been demonstrated that multiple microRNAs (miRNAs or miRs) are aberrantly expressed in retinoblastoma (RB) and contribute to RB initiation and progression. miR‑382 has been revealed to be aberrantly expressed and therefore exhibits a key role in the progression of various types of cancer. However, the expression pattern, functional roles and underlying molecular mechanism of miR‑382 in RB remain unknown. The present study investigated the expression levels of miR‑382 and its effects on RB cells and the underlying regulatory mechanism of its action. It was demonstrated that miR‑382 was downregulated in RB tissues and cell lines. Upregulation of miR‑382 inhibited RB cell proliferation and invasion in vitro. Additionally, brain‑derived neurotrophic factor (BDNF) was identified as a novel target of miR‑382 in RB. BDNF was upregulated in RB tissues and negatively associated with miR‑382 expression levels. Furthermore, BDNF overexpression rescued the tumour‑suppressing effects on RB cells induced by miR‑382. miR‑382 inactivated the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signalling pathway in RB. These findings suggested that miR‑382 serves as a tumour suppressor in RB, in part, by targeting the BDNF‑mediated PI3K/AKT signalling pathway. The results of the present study suggest a potential therapeutic strategy for treating RB patients in the future.

show abstract

“…27 Previous studies on specific cancer gene therapy paid close attention to tumour-selective delivery systems, but they had difficulties in achieving satisfactory effect because of side effects. 4,[28][29][30] We therefore proposed a new strategy to deal with the limitation from the use of vectors. The tumour-preferential Frizzled-7 promoter and Shiga toxin receptor The Frizzled-7 has been demonstrated as a critical receptor for the Wnt signalling and is involved in tumorigenesis and metastasis in many cancer types, including gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Shiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter

Peng

Shen

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Objectives: Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins. Methods:The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7-Stx1 plasmid vectors with tumour-preferential Frizzled-7 promoter and Stx1. pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7-Stx1.Results: Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7-Stx1.Conclusion: Frizzled-7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled-7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.Taken together, the Frizzled-7 promoter is preferentially active and Gb3 is abundant in gastric cancer cells. An improved and comprehensive understanding of these and future methods that combine use of the Frizzled-7 promoter and Stx1 will define possibly definitive inhibiting of gastric cancer cell proliferation.

show abstract

MicroRNA‐9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8

Abstract: Our results suggested that MicroRNA-9-TNFAIP8 might represent a promising diagnostic biomarker for GC patients and could be a potential therapeutic target in the prevention and treatment of GC.

Cited by 32 publications

References 39 publications

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

MicroRNA-382 inhibits cell proliferation and invasion of retinoblastoma by targeting BDNF-mediated PI3K/AKT signalling pathway

Shiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter

Contact Info

Product

Resources

About